Eli Lilly Boosts 2026 Forecast as GLP-1 Demand Surges
Skyrocketing demand for diabetes drug Mounjaro and obesity treatment Zepbound continues to drive record-breaking financial results for the firm. Mounjaro sales reached $8.7 billion, while Zepbound added $4.2 billion, both exceeding market